MMP9 and endometrial endometrioid carcinoma: demonstrated that miR-22 could effectively reverse E2-induced cell proliferation and invasion of tumor cells in endometrial endometrioid carcinomas (EECs) by inhibiting Cyclin D1 expression and the secretion of matrix metalloproteinase (MMP)-2 and MMP-9.